XTL Biopharma files to raise $40m on Nasdaq
Teva will have to sell its generic versions of three Cephalon brand drugs.
The Federal Trade Commission (FTC) has approved Teva Pharmaceutical Industries Ltd's (Nasdaq: TEVA; TASE: TEVA) acquisition of Cephalon Inc. (Nasdaq: CEPH), and granted early termination of waiting period under the HartScottRodino Antitrust Improvements Act of 1976.
As part of the approval, Teva will sell two Abbreviated New Drug Applications (ANDA) for its generic versions of Cephalon drugs: cancer treatment Actiq and muscle relaxant Amrix. According to IMS Health data brand Actiq has $173 million in annual sales in the US, and Amrix has $125 million. Teva will also grant its non-exclusive US rights to its generic version of Cephalon's Provigil to a third party. Provigil has $1.1 billion in annual US sales. Provigil is a treatment for improving wakefulness in people with sleep apnea and narcolepsy.
Teva and Cephalon are still waiting for approval of the merger by the EU European Antitrust Commission, after which they expect to close the merger by October 14.
In a separate development, Teva's British subsidiary Teva UK Ltd. obtained marketing approval for its generic Salmeterol pMDI inhaler, the first company to obtain this permission. Salmeterol treats asthma caused by exercise and at night in adults and adolescents over 12 years of age, as well as breathing problems caused by other chest diseases known as chronic obstructive pulmonary disease (COPD) or chronic bronchitis in adults. Brand Salmeterol is made by GlaxoSmithKline plc (NYSE; LSE: GSK).
Teva's share price fell 2.2% on Nasdaq on Friday to $36.75, giving a market cap of $34.5 billion, and fell 1.4% in morning trading on the TASE to NIS 137.80.
Published by Globes [online], Israel business news - www.globes-online.com - on October 9, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
You comment was recieved and soon will be published.
Load more comments
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.